Immunologic Mechanisms of Alcoholic Liver Disease

酒精性肝病的免疫学机制

基本信息

项目摘要

Our laboratory has been actively studying the pathogenesis of alcoholic liver disease, focusing on the role of acetaldehyde dehydrogenase 2 (ALDH2) and prednisolone in alcoholic liver injury, and we have also developed a mouse model of chronic plus binge ethanol feeding model, which represents early stages of human alcoholic steatohepatitis. Chronic alcohol consumption is a leading cause of chronic liver disease worldwide, leading to cirrhosis and hepatocellular carcinoma. Currently, the most widely used model for alcoholic liver injury is ad libitum feeding with the Lieber-DeCarli liquid diet containing ethanol for 4-6 weeks; however, this model, without the addition of a secondary insult, only induces mild steatosis, slight elevation of serum alanine transaminase (ALT) and little or no inflammation. During this reporting period, we developed a simple mouse model of alcoholic liver injury by chronic ethanol feeding (10-d ad libitum oral feeding with the Lieber-DeCarli ethanol liquid diet) plus a single binge ethanol feeding. This chronic-plus-single-binge ethanol feeding synergistically induces liver injury, inflammation and fatty liver, which mimics acute-on-chronic alcoholic liver injury in patients. Chronic-binge ethanol feeding leads to high blood alcohol levels; thus, this simple model will be very useful for the study of alcoholic liver disease (ALD) and of other organs damaged by alcohol consumption. Aldehyde dehydrogenase 2 (ALDH2) is the major enzyme that metabolizes acetaldehyde produced from alcohol metabolism. Approximately 40 to 50% of East Asians carry an inactive ALDH2 gene and exhibit acetaldehyde accumulation after alcohol consumption. However, the role of ALDH2 deficiency in the pathogenesis of alcoholic liver injury remains obscure. During this reporting period, we have used wild-type (WT) and ALDH2-/- mice to examine the roles of ALDH2 in alcoholic liver injury and fibrosis by using ethanol feeding and/or carbon tetrachloride (CCl4) treatment. Compared with WT mice, ethanol-fed ALDH2-/- mice had higher levels of malondialdehyde and acetaldehyde (MAA) adduct and greater hepatic inflammation, with higher hepatic interleukin-6 (IL-6) expression but surprisingly lower levels of steatosis and serum ALT. Higher IL-6 levels were also detected in ethanol-treated precision-cut-liver slices from ALDH2-/- mice and in Kupffer cells isolated from ethanol-fed ALDH2-/- mice than those levels in WT mice. In vitro incubation with MAA enhanced the LPS-mediated stimulation of IL-6 production in Kupffer cells. In agreement with these findings, hepatic activation of the major IL-6 downstream signaling molecule signal transducer and activator of transcription 3 (STAT3) was higher in ethanol-fed ALDH2-/- mice than in WT mice. An additional deletion of hepatic STAT3 resulted in increased steatosis and hepatocellular damage in ALDH2-/- mice. Finally, ethanol-fed ALDH2-/- mice were more prone to CCl4-induced liver inflammation and fibrosis than ethanol-fed WT mice. CONCLUSIONS: ALDH2-/- mice are resistant to ethanol-induced steatosis but prone to inflammation and fibrosis via MAA-mediated paracrine activation of IL-6 in Kupffer cells. These findings suggest that ALDH2-deficient individuals may be resistant to steatosis, but are prone to liver inflammation and fibrosis following alcohol consumption. Prednisolone is a corticosteroid that has been used to treat inflammatory liver diseases, such as autoimmune hepatitis and alcoholic hepatitis. However, the results have been controversial, and how prednisolone affects liver disease progression remains unknown. During this reporting period, we examined the effect of prednisolone treatment on several models of liver injury, including T/NKT cell hepatitis induced by concanavalin A (Con A) and -galactosylceramide (-GalCer), and hepatotoxin-mediated hepatitis induced by carbon tetrachloride (CCl4). Prednisolone administration attenuated ConA- and -GalCer-induced hepatitis and systemic inflammatory responses. Treating mice with prednisolone also suppressed inflammatory responses in a model of hepatotoxin (CCl4)-induced hepatitis, but surprisingly exacerbated liver injury and delayed liver repair. Immunohistochemical and flow cytometric analyses demonstrated that prednisolone treatment inhibited hepatic macrophage and neutrophil infiltration in CCl4-induced hepatitis and suppressed their phagocytic activities in vivo and in vitro. Macrophage and/or neutrophil depletion aggravated CCl4-induced liver injury and impeded liver regeneration. Finally, conditional disruption of glucocorticoid receptor in macrophages and neutrophils abolished prednisolone-mediated exacerbation of hepatotoxin-induced liver injury. Conclusion: Prednisolone treatment prevents T/NKT cell hepatitis but exacerbates hepatotoxin-induced liver injury by inhibiting macrophage- and neutrophil-mediated phagocytic and regenerative functions. These findings may not only increase our understanding of the steroid treatment mechanism but also help us to better manage steroid therapy in liver diseases. In addition, we are also collaborating with Drs. George Kunos and Pal Pacher from NIAAA to investigate the role of the endocannabinoid system in alcoholic liver disease.
我们实验室一直积极研究酒精性肝病的发病机制,重点关注乙醛脱氢酶2 (ALDH2)和强的松龙在酒精性肝损伤中的作用,并建立了慢性加暴饮乙醇喂养模型小鼠模型,代表了人类酒精性脂肪性肝炎的早期阶段。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

bin gao其他文献

bin gao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('bin gao', 18)}}的其他基金

ETHANOL AND IL6 SIGNAL TRANSDUCTION
乙醇和 IL6 信号转导
  • 批准号:
    2894248
  • 财政年份:
    1998
  • 资助金额:
    $ 88.82万
  • 项目类别:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
  • 批准号:
    2633945
  • 财政年份:
    1998
  • 资助金额:
    $ 88.82万
  • 项目类别:
ETHANOL AND IL6 SIGNAL TRANSDUCTION
乙醇和 IL6 信号转导
  • 批准号:
    2558838
  • 财政年份:
    1998
  • 资助金额:
    $ 88.82万
  • 项目类别:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
  • 批准号:
    6172833
  • 财政年份:
    1998
  • 资助金额:
    $ 88.82万
  • 项目类别:
TISSUE SPECIFIC CNTRL ALPHA 1B ANDRENOCEPTOR EXPRESSION
组织特异性 CNTRL ALPHA 1B 雄激素受体表达
  • 批准号:
    2895764
  • 财政年份:
    1998
  • 资助金额:
    $ 88.82万
  • 项目类别:
Innate immunity and cytokines in liver disease
肝病中的先天免疫和细胞因子
  • 批准号:
    8148175
  • 财政年份:
  • 资助金额:
    $ 88.82万
  • 项目类别:
Mechanisms of Alcoholic Liver Disease
酒精性肝病的机制
  • 批准号:
    7591944
  • 财政年份:
  • 资助金额:
    $ 88.82万
  • 项目类别:
Molecular Mechanism For Resistance To Interferon Therapy
干扰素治疗耐药的分子机制
  • 批准号:
    6675119
  • 财政年份:
  • 资助金额:
    $ 88.82万
  • 项目类别:
Mechanisms of Alcoholic Liver Disease
酒精性肝病的机制
  • 批准号:
    7963847
  • 财政年份:
  • 资助金额:
    $ 88.82万
  • 项目类别:
Biological Significance and Therapeutic Potential of Cyt
细胞色素的生物学意义和治疗潜力
  • 批准号:
    6818687
  • 财政年份:
  • 资助金额:
    $ 88.82万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 88.82万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了